Coastline Trust’s Verrica Pharmaceuticals VRCA Stock Holding History

Coastline Trust’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6	Closed	-$42	–	428
2024 Q4	$42	Sell	6 -14	-70%	-$154	﹤0.01%	428
2024 Q3	$290	Buy	+20	New	+$901	﹤0.01%	426

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return

Coastline Trust's VRCA Position: Q1 2025 in Review

Coastline Trust sold out of Verrica Pharmaceuticals (VRCA) in Q1 2025, closing a stake of 6 shares — an estimated $42 sold.

Coastline Trust first reported a position in VRCA in Q3 2024 and held it in 2 quarters. The position peaked at $290 in Q3 2024. 74 funds tracked by Wall St. Rank hold VRCA as of Q1 2025.

Coastline Trust reported no remaining Verrica Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Coastline Trust sold 6 Verrica Pharmaceuticals shares in Q1 2025, an estimated $42.
Coastline Trust first reported a position in Verrica Pharmaceuticals in Q3 2024 and held it in 2 quarters.
Coastline Trust's Verrica Pharmaceuticals position peaked at $290 in Q3 2024.
74 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2025.

Based on Coastline Trust's 13F filing for Q1 2025, filed 28 Apr 2025.